MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
Capital repatriation isn't a retreat — it’s Hong Kong’s regulatory graduation
Hong Kong should build the Asia–Latin America investment corridor
Why Hong Kong's carried interest reform matters, and why it isn't a zero-sum play